Hutchmedchinalimited Is A Biopharmaceutical Company Focused On The Discoverydevelopmentand Commercialization Of Innovative Therapeuticsprimarily In Oncology And Immunologyheadquartered In Hong Kong And Registered In The Cayman Islandshutchmed Is Listed On Both Nasdaq And The Hong Kong Stock Exchange The Company Emphasizes Research And Developmentinvesting Significantly To Create Targeted Therapies For Cancer And Immunological Diseaseshutchmed Has A Robust Clinical Pipeline With Over 15 Clinical Stage Drug Candidatesincluding Six Internally Discovered Moleculesits Key Products Include Surufatiniborpathysfor Neuroendocrine Tumorsfruquintinibelunatefor Colorectal Cancerand Savolitiniba Precision Oncology Therapyhutchmed Aims To Ensure Its Approved Drugs Reach Patients Globallywith A Primary Market In China And An Expanding Presence In The United States And Europethe Company Employs Over 1 200 Personnelreflecting Its Commitment To Innovation In The Biopharmaceutical Sector
